Literature DB >> 24102013

Malignant pleural mesothelioma: current and future perspectives.

Konstantinos Porpodis1, Paul Zarogoulidis, Efimia Boutsikou, Antonis Papaioannou, Nikolaos Machairiotis, Kosmas Tsakiridis, Nikolaos Katsikogiannis, Bojan Zaric, Branislav Perin, Haidong Huang, Ioanna Kougioumtzi, Dionysios Spyratos, Konstantinos Zarogoulidis.   

Abstract

Mesothelioma still remains an occupational related cancer with severe outcome. It is usually diagnosed at advanced stage since it does not demonstrate early symptoms. Several efforts have been made towards removing all materials inducing mesothelioma in the work setting and new work protection measures have been applied. Although we have new targeted treatments and radical surgery as arrows in the quiver, the type of mesothelioma and early diagnosis still remain the best treatment approach. Novel treatment modalities have been explored and several others are already on the way. In the current review we will present current data for mesothelioma and future perspectives.

Entities:  

Keywords:  Mesothelioma; diagnosis; pathogenesis; targeted treatment; treatment

Year:  2013        PMID: 24102013      PMCID: PMC3791499          DOI: 10.3978/j.issn.2072-1439.2013.08.08

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  112 in total

1.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

2.  Optimising therapy for EGFR-addicted NSCLC: just the start.

Authors:  Ramaswamy Govindan; Janakiraman Subramanian
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

3.  Inhibition of the met receptor in mesothelioma.

Authors:  Toru Mukohara; Gabriel Civiello; Ian J Davis; Michele L Taffaro; James Christensen; David E Fisher; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

4.  Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.

Authors:  B Castagneto; S Zai; L Mutti; A Lazzaro; R Ridolfi; E Piccolini; A Ardizzoni; L Fumagalli; G Valsuani; M Botta
Journal:  Lung Cancer       Date:  2001 Feb-Mar       Impact factor: 5.705

5.  High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Authors:  Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke
Journal:  Clin Cancer Res       Date:  2010-10-18       Impact factor: 12.531

6.  Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

Authors:  Coleman K Obasaju; Zhishen Ye; Antoinette J Wozniak; Chandra P Belani; Mary-Louise Keohan; Helen J Ross; Jonathan A Polikoff; David M Mintzer; Matthew J Monberg; Pasi A Jänne
Journal:  Lung Cancer       Date:  2006-11-07       Impact factor: 5.705

7.  Eighth international mesothelioma interest group.

Authors:  M Carbone; S M Albelda; V C Broaddus; R M Flores; G Hillerdal; M-C Jaurand; K Kjaerheim; H I Pass; B Robinson; A Tsao
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

8.  Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

Authors:  A P Chahinian; K Antman; M Goutsou; J M Corson; Y Suzuki; C Modeas; J E Herndon; J Aisner; R R Ellison; L Leone
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

9.  Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.

Authors:  Lee M Krug; Tracy Curley; Lawrence Schwartz; Stacie Richardson; Paul Marks; Judy Chiao; W Kevin Kelly
Journal:  Clin Lung Cancer       Date:  2006-01       Impact factor: 4.785

10.  Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study.

Authors:  Isabelle Monnet; Jean-Luc Breau; Denis Moro; Hervé Lena; Jean-Christophe Eymard; Olivier Ménard; Jean-Philippe Vuillez; Mohamed Chokri; Jean-Loup Romet-Lemonne; Manuel Lopez
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

View more
  16 in total

1.  Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.

Authors:  Jianting Ma; Shengzhi Zhang
Journal:  World J Surg Oncol       Date:  2022-06-29       Impact factor: 3.253

2.  Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.

Authors:  Luca Ampollini; Elisabetta Barocelli; Andrea Cavazzoni; Piergiorgio Petronini; Claudio Mucchino; Anna Maria Cantoni; Fabio Leonardi; Luigi Ventura; Stefano Barbieri; Paolo Colombo; Antonella Fusari; Paolo Carbognani; Michele Rusca; Fabio Sonvico
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

3.  Mesothelioma: A Case in a Diagnostic Timeline and the Efficiency of Robot-Assisted Surgery.

Authors:  Paul Zarogoulidis; Kosmas Tsakiridis; Thomas Zarampoukas; Katerina Zarampouka; Dimitris Hatzibougias; Christos Tolis; Stavros Tryfon; Maria Saroglou; Aris Ioannidis; Dimitris Matthaios; Christoforos Kosmidis
Journal:  Case Rep Oncol       Date:  2022-03-03

4.  A novel link between FMR gene and the JNK pathway provides clues to possible role in malignant pleural mesothelioma.

Authors:  Ajay Srivastava
Journal:  FEBS Open Bio       Date:  2015-08-19       Impact factor: 2.693

5.  A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.

Authors:  Yuji Tada; Kenzo Hiroshima; Hideaki Shimada; Naoya Morishita; Toshiro Shirakawa; Kunio Matsumoto; Masato Shingyoji; Ikuo Sekine; Koichiro Tatsumi; Masatoshi Tagawa
Journal:  Springerplus       Date:  2015-07-16

6.  Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma.

Authors:  Michael Tayao; Juliana Andrici; Mahtab Farzin; Adele Clarkson; Loretta Sioson; Nicole Watson; Terence C Chua; Tamara Sztynda; Jaswinder S Samra; Anthony J Gill
Journal:  PLoS One       Date:  2016-03-16       Impact factor: 3.240

7.  Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines.

Authors:  Lourdes Cortes-Dericks; Laurene Froment; Gregor Kocher; Ralph A Schmid
Journal:  Stem Cell Res Ther       Date:  2016-02-09       Impact factor: 6.832

8.  Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).

Authors:  C Raynaud; L Greillier; J Mazieres; I Monnet; B Mastroianni; G Robinet; G Fraboulet; A Dixmier; H Berard; R Lamy; J Letreut; H Lena; G Oliviero; S Botta; A Vergnenegre; I Borget; C Chouaid
Journal:  BMC Cancer       Date:  2015-11-06       Impact factor: 4.430

Review 9.  Primary solitary fibrous tumors of liver: a case report and literature review.

Authors:  Qiang Liu; Jing Liu; Wenyou Chen; Shunbao Mao; Yihe Guo
Journal:  Diagn Pathol       Date:  2013-12-02       Impact factor: 2.644

10.  An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.

Authors:  Yuji Tada; Kenzo Hiroshima; Hideaki Shimada; Masato Shingyoji; Toshio Suzuki; Hiroki Umezawa; Ikuo Sekine; Yuichi Takiguchi; Koichiro Tatsumi; Masatoshi Tagawa
Journal:  Springerplus       Date:  2016-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.